【レポートの概要（一部）】
1. Report Overview
1.1 Introduction to that Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered
1.7 Who is This Study For?
1.8 Research and Analysis Methods
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Global Diabetes Drug Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2015-2025
3.1 The World Diabetes Drug Market, 2014
3.1.1 Diabetes Treatment Market by Drug Class, 2014
3.1.2 Top Selling Diabetes Drugs, 2014
3.1.3 Generic Anti Diabetes Drugs, 2014
3.1.4 Top 10 Diabetes Drug Producers, 2014
3.2 World Diabetes Drugs Market: Revenue Forecast, 2015-2025
4. Human Insulin and Analogues Market, 2015-2025
4.1 Insulin and Insulin Analogues Drugs, 2014
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2015-2025
4.3 Insulin and Insulin Analogues: Market Trends, 2015-2025
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2015-2025
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast,
2015-2025
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2015-2025
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast,
2015-2025
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2015-2025
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast,
2015-2025
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2015-2025
5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2015-2025
5.1 DPP-4 Market, 2014
5.2 DPP-4 Inhibitors Revenue Forecast, 2015-2025
5.3 Januvia (Sitagliptin; Merck & Co.): Revenue Forecast, 2015-2025
5.4 Janumet (Sitagliptin and Metformin; Merck & Co.): Revenue Forecast, 2015-2025
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2015-2025
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2015-2025
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2015-2025
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2015-2025
6. Sulfonylureas Market, 2015-2025
6.1 Sulfonylureas Market, 2014
6.2 Sulfonylureas: Revenue Forecast, 2015-2025
6.3 Sulfonylureas: Market Trends 2015-2025
6.3.1 New Opportunities for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2015-2025
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2015-2025
6.6 Glucotrol (Glipizide; Pfizer): Revenue Forecast, 2015-2025
7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, 2015-2025
7.1 GLP-1 Receptor Agonists Market, 2014
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2015-2025
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2015-2025
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost the Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2015-2025
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025
8. Alpha-glucosidase Inhibitors Market, 2015-2025
8.1 Alpha-glucosidase Inhibitors Market, 2014
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2015-2025
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2015-2025
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2015-2025
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2015-2025
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2015-2025
9. Meglitinides Market, 2015-2025
9.1 Meglitinides Market, 2014
9.2 Meglitinides: Revenue Forecast, 2015-2025
9.2.1 Meglitinides: Market Trends, 2015-2025
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2015-2025
9.4 Sarlix (Nateglinide; Novartis): Revenue Forecast, 2015-2025
9.5 Glufast (Acarbose; Bayer): Revenue Forecast, 2015-2025
10. Thiazolidinediones Market, 2014
10.1 Thiazolidinediones Market Overview, 2014
11. Sodium-glucose Co-transporter-2 (SGLT2) Inhibitors Market, 2015-2025
11.1 SGLT2 Inhibitors Market, 2014
11.2 SGLT2 Revenue Forecast, 2015-2025
11.2.1 SGLT2 Market Trends, 2015-2025
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2015-2025
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2015-2025
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2015-2025
12. Biguanides Market, 2015-2025
12.1 Biguanides Market, 2014
12.2 Biguanides: Revenue Forecast, 2015-2025
12.2.1 Biguanides: Market Trends, 2015-2025
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck & Co): Revenue Forecast, 2015-2025
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2015-2025
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2015-2025
13. National Markets for Diabetes Drugs, 2015-2025
13.1 Leading National Markets for Diabetes Drugs, 2014
13.2 Leading National Diabetes Drugs Market: Revenue Forecast,
2015-2025
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2015-2025
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast 2015-2025
13.4.1 Increased Governmental Investment Will Drive Market Growth
13.4.2 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.3 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2014
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market: Revenue Forecasts, 2015-2025
13.5.1.1 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2015-2025
13.5.1.2 Great Standard of Care and Regulatory Reforms in France – Revenue Forecast 2015-2025
13.5.1.3 Austerity Measures in Spain Discourage Companies – Revenue Forecast 2015-2025
13.5.1.4 UK: High Burden of Diabetes Costs on the UK NHS
13.5.1.5 Italy: Stable Market with Good Standards of Care – Revenue Forecast, 2015-2025
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2015-2025
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2015-2025.
13.7.1 Focus on the Rural Population
13.8 Introduction of Novel Therapies in the Russian Federation – Revenue Forecast, 2015-2025
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2015-2025
13.9.1 Localized Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market R&D Pipeline, 2015
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (LY2963016 Eli Lilly and Boehringer Ingelheim): US Approval Delay May Trigger High Revenues
14.2.2 Insulin Glargine (U300 Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin. Will it Reach $1bn Sales?
14.3 Human Insulins and Analogues: Pipeline Developments, 2015
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 Basal Insulin Peglispro-BIL (Eli Lilly): Holding Promise – What Will More Testing Bring?
14.3.3 MK-1293 (Merck & Co. and Biogen Idec): Another Biosimilar of Lantus on the Way
14.3.4 OG217SC (Novo Nordisk)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex) Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck & Co.)
14.4.3 ARI-2243 (Arisaph)
14.5 GLP-1: New Approvals and Pipeline, 2015
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Does it have the Potential to Reach Blockbuster Status?
14.5.2 Tanzeum (Albiglutide; GSK)
14.5.3 Semaglutide (NN9535; Novo Nordisk)
14.5.4 Xultophy (formerly IDegLira; Novo Nordisk)
14.5.5 ITC650 (Intarcia Therapeutics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2015
14.6.1 Suglat (Ipragliflozin; Astellas Pharma/Kotobuki)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 Lusefi (Luseogliflozin; Taisho Pharmaceutical)
14.7 Other Anti Diabetes Drugs: Pipeline Developments, 2015
14.7.1 DM199 (DiaMedica)
14.7.2 DiaPep277 (Andromeda Biotech)
14.7.3 Glucokinase Activators
14.7.4 ZYGK1 (Zydus Cadila Healthcare)
14.7.5 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2015-2025
15.1 SWOT Analysis of the Diabetes Drug Market, 2015-2025
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to Copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues
16. Research Interviews
16.1 Interview with an Academic Involved in Diabetes R&D
16.1.1 The Insulin Drug Market
16.1.2 Novel Delivery Technologies
16.1.3 Future Developments and Market Prospects
16.2 Interview with James Anderson, Generex Biotechnology Corporation
16.2.1 The Current Diabetes Drug Market
16.2.2 Generex’s Oral-lyn™ Product and Buccal Drug Delivery
17. Conclusions from the Research and Analysis
17.1 The Diabetes Market – Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2015-2025
17.2.1 Insulin Will Continue to Dominate the Market
17.3 Regional Outlooks for That Market, 2015-2025
17.4 Future Opportunities
【レポート販売概要】
■ タイトル：糖尿病治療薬の世界市場：インスリン、DPP-4、スルホニルウレア、αグルコシダーゼ阻害剤、チアゾリジンジオン、SGLT2阻害薬、ビグアニド等■ 英文：Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5050814
■ 調査対象地域：グローバル
- 世界のユーティリティ分析及びエネルギー分析市場There is a critical global need to save energy by controlling and reducing energy consumption. This will help the world to reduce costs, environmental damage and the risk of energy supply shortage. Energy Analytics help companies to crunch large amounts of data and reduce their energy costs. Businesses are fast adapting to this trend with the help of a variety of innovative solutions for efficient …
- セザリー症候群(Sezary Syndrome)：世界の治験レビュー（2015年上半期版）Sezary Syndrome Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as …
- 世界の艦艇及び水上戦闘艦艇市場動向2013-2023：トレンド、開発動向及び課題Technological Developments in the global Naval Vessels and Surface Combatants include: Anti-mine warfare is a critical mission for the US Navy, as it faces threats from countries such as Iran that could possibly disrupt the global economy by planting mines in crucial commercial waterways
- 世界における幹細胞移植（腫瘍内科）のパイプライン分析2015Summary DelveInsight’s, “Stem Cells Transplantation in Oncology -Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mode of therapy. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Stem Cells Oncology. • The Report gives insights on 20+ products with 15+ companies, which are active in this fie …
- 光ファイバー・テスト装置の世界市場：OTDR（光パルス試験器）、OPM、OLTS、RFTS、光スペクトルアナライザーFiber optics is the science of transmitting data, voice, and images by the passage of light through thin, transparent fibers. A fiber optic consists of a bundle of glass threads, each of which is capable of transmitting messages modulated onto light waves. Fiber optic testing is gaining value due to its growing applications in the installation and maintenance of fiber optic cables. The major end-u …
- 自動車用リーフスプリング式サスペンションの世界市場ABSTRACTAbout Automotive Leaf Spring Suspension Automotive leaf spring suspension is an arc-shaped spring steel mainly used in heavy commercial vehicles. It can be attached either at the rear or front of the vehicles to provide suspension. There is a high penetration of the automotive leaf spring suspension market in the M&HCVs segment in APAC. This region is the biggest market for automotive leaf …
- 皮膚科治療薬市場（2014-2024）Dermatological drugs – new study showing you trends, R&D progress, and predicted revenues Where’s the dermatological drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 272-page report provides 169 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market p …
- 地域熱供給の世界市場予測（～2023年）“Increasing demand for energy-efficient and cost-effective heating systems to drive overall growth of district heating market” The district heating market is expected to grow from USD 170.7 billion in 2018 to USD 203.0 billion by 2023, at a compound annual growth rate (CAGR) of 3.5% during the forecast period. The district heating market is driven by various factors such as increasing demand for e …
- Galp Energia SGPS S.A.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Galp Energia SGPS S.A. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Galp Energia SGPS S.A. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- 片頭痛（Migraine）：企業動向PharmaPoint: Migraine - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Migraine - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The repo …
- 建設機械の世界市場予測（～2021）The construction equipment market is projected to grow at a CAGR of 4.11% during the forecast period, to reach a market size of USD 116.20 Billion by 2021, while the mining equipment market is projected to grow at a CAGR of 6.42%, to reach USD 136.03 Billion by 2021. A wide array of upcoming infrastructural projects and the rising demand for commodities has led to an increase in construction and m …
- クロスフローメンブレンの世界市場：逆浸透膜濾過、限外濾過、精密濾過、ナノ濾過About Cross Flow Membrane Cross flow filtration, also known as tangential flow filtration, is a process in which the feed flows parallel to or tangentially across the surface of the membrane, rather than perpendicular to it, as is the case in conventional filtration processes. The principal advantages of cross flow filtration are: • Longer duration of filtration as the filter cake is constantly wa …
- 皮なめし機械の世界市場2016-2020About Tanning Tanning is an integral part of the entire leather production process. It is the conversion of the protein of raw skin or hide into a material that is stable. The process ensures that the hide or converted material does not decompose and is suitable for end-user applications. Technavio’s analysts forecast the global leather tanning machinery market to grow at a CAGR of 3.99% during th …
- アラビアガムの世界市場Presently, the demand for confectionery and beverage products is increasing in Asia-Pacific, mainly owing to the increasing disposable incomes of consumers from developing countries of the region. The confectionery segment is the largest application segment in the global gum arabic market, wherein it is used as a stabilizer, thickener, and texturant. With the rising disposable incomes of consumers …
- 爪真菌症(爪白癬)(Onychomycosis (Tinea Unguium))：世界の治験レビュー2014年下半期版Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014" provides data on the Onychomycosis (Tinea Unguium) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Onychomycosis (Tinea Unguium). It includes an overv …
